| scholarly article | Q13442814 |
| P50 | author | Thomas Giordano | Q37621567 |
| P2093 | author name string | M A Nikiforov | |
| E V Prochownik | |||
| S Patil | |||
| D Zhuang | |||
| A E Berman | |||
| S Mannava | |||
| M S Soengas | |||
| J A Wawrzyniak | |||
| V Grachtchouk | |||
| W-H Tang | |||
| P2860 | cites work | TRRAP-dependent and TRRAP-independent transcriptional activation by Myc family oncoproteins | Q24540114 |
| WAF1, a potential mediator of p53 tumor suppression | Q27861121 | ||
| A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage | Q28138556 | ||
| Determinants of BRAF mutations in primary melanomas | Q28191720 | ||
| Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases | Q28345479 | ||
| ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence | Q28591778 | ||
| Distinct sets of genetic alterations in melanoma | Q29614965 | ||
| p53-dependent apoptosis modulates the cytotoxicity of anticancer agents | Q29615031 | ||
| Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas | Q29616243 | ||
| Restoration of p53 function leads to tumour regression in vivo | Q29618727 | ||
| BRAFE600-associated senescence-like cell cycle arrest of human naevi | Q29619550 | ||
| Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence | Q29620428 | ||
| Inactivation of the apoptosis effector Apaf-1 in malignant melanoma | Q31984891 | ||
| MYC oncogenes and human neoplastic disease | Q33667340 | ||
| Transformation of human and murine fibroblasts without viral oncoproteins | Q33925306 | ||
| Tumor suppressors and oncogenes in cellular senescence. | Q33930350 | ||
| Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations | Q33998283 | ||
| Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay | Q34005199 | ||
| Melanocyte development and malignant melanoma | Q34047114 | ||
| High frequency of BRAF mutations in nevi | Q34160519 | ||
| Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16(INK4a). | Q34574445 | ||
| Contributions of Myc to tumorigenesis | Q34605526 | ||
| The INK4a/ARF locus and melanoma | Q35146563 | ||
| Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation | Q35928960 | ||
| The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma | Q36170391 | ||
| Role of the unfolded protein response in cell death | Q36351719 | ||
| Genetic alterations in signaling pathways in melanoma | Q36445920 | ||
| Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway | Q36557277 | ||
| Malignant melanoma: genetics and therapeutics in the genomic era. | Q36567158 | ||
| Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. | Q36572080 | ||
| The Myc oncoprotein as a therapeutic target for human cancer | Q36578165 | ||
| Conditional transgenic models define how MYC initiates and maintains tumorigenesis | Q36578360 | ||
| Oncogene-induced cell senescence--halting on the road to cancer | Q36587198 | ||
| Melanoma biology and new targeted therapy | Q36742015 | ||
| Wild-type p53: tumors can't stand it. | Q36756803 | ||
| Expanding mTOR signaling | Q36902840 | ||
| Normal human fibroblasts are resistant to RAS-induced senescence | Q37012141 | ||
| The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. | Q37033473 | ||
| Werner syndrome protein limits MYC-induced cellular senescence | Q39895677 | ||
| A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. | Q40200783 | ||
| Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors | Q40444060 | ||
| Ha-Ras(G12V) induces senescence in primary and immortalized human esophageal keratinocytes with p53 dysfunction | Q40531824 | ||
| c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle | Q42115767 | ||
| Inhibition of c-Myc oncoprotein limits the growth of human melanoma cells by inducing cellular crisis | Q44489695 | ||
| The power and the promise of oncogene-induced senescence markers. | Q53345760 | ||
| Immortalization of primary human prostate epithelial cells by c-Myc. | Q53359625 | ||
| Tumor suppressor p16INK4a determines sensitivity of human cells to transformation by cooperating cellular oncogenes | Q53374378 | ||
| Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. | Q53600237 | ||
| c-MYC and nodular malignant melanoma. A case report | Q74008872 | ||
| Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma | Q74171412 | ||
| P4510 | describes a project that uses | ImageQuant | Q112270642 |
| P433 | issue | 52 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | overexpression | Q61643320 |
| P304 | page(s) | 6623-6634 | |
| P577 | publication date | 2008-08-04 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells | |
| P478 | volume | 27 |
| Q50667628 | A Theoretical Study on Inhibition of Melanoma with Controlled and Targeted Delivery of siRNA via Skin Using SPACE-EGF. |
| Q40101469 | A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF. |
| Q37386014 | A genomic screen identifies TYRO3 as a MITF regulator in melanoma. |
| Q36096818 | A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines |
| Q50027280 | AMPK promotes survival of c-Myc-positive melanoma cells by suppressing oxidative stress. |
| Q39362670 | Absence of distinguishing senescence traits in human melanocytic nevi |
| Q37529969 | Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells |
| Q37818577 | Advances in melanoma senescence and potential clinical application. |
| Q36243554 | B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer |
| Q35356498 | BCYRN1, a c-MYC-activated long non-coding RNA, regulates cell metastasis of non-small-cell lung cancer |
| Q93081301 | C2-Ceramide-Induced Rb-Dominant Senescence-Like Phenotype Leads to Human Breast Cancer MCF-7 Escape from p53-Dependent Cell Death |
| Q37621777 | Cancer stem cells: a reality, a myth, a fuzzy concept or a misnomer? An analysis |
| Q37743042 | Cdk2: a key regulator of the senescence control function of Myc. |
| Q35947022 | Cellular senescence and cancer chemotherapy resistance |
| Q33953067 | Cellular senescence and protein degradation: breaking down cancer |
| Q41002619 | Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. |
| Q35605096 | Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect |
| Q38055308 | Controversial aspects of oncogene-induced senescence |
| Q54453884 | Cystathionase mediates senescence evasion in melanocytes and melanoma cells. |
| Q34646614 | Dabrafenib and its potential for the treatment of metastatic melanoma |
| Q41585228 | Detection of Nucleotide Disbalance in Cells Undergoing Oncogene-Induced Senescence |
| Q37618297 | ERK and cell death: mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence |
| Q37967610 | Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review |
| Q42024622 | Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors. |
| Q37531849 | Epigenetics in human melanoma |
| Q40207035 | Epstein-Barr Virus Rta-Mediated Accumulation of DNA Methylation Interferes with CTCF Binding in both Host and Viral Genomes. |
| Q33851707 | Epstein-Barr virus (EBV) Rta-mediated EBV and Kaposi's sarcoma-associated herpesvirus lytic reactivations in 293 cells. |
| Q37492244 | Facilitating replication under stress: an oncogenic function of MYC? |
| Q37881690 | Finding the root of the problem: the quest to identify melanoma stem cells |
| Q39312161 | Focus on cutaneous and uveal melanoma specificities. |
| Q36326842 | Functional characterization of RAD52 as a lung cancer susceptibility gene in the 12p13.33 locus |
| Q43494554 | Human endogenous retrovirus K (HERV-K) rec mRNA is expressed in primary melanoma but not in benign naevi or normal skin |
| Q91142521 | KLF9-dependent ROS regulate melanoma progression in stage-specific manner |
| Q91081385 | Lineage-specific control of TFIIH by MITF determines transcriptional homeostasis and DNA repair |
| Q28534280 | Liver-specific expressions of HBx and src in the p53 mutant trigger hepatocarcinogenesis in zebrafish |
| Q34248882 | MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms |
| Q39406924 | MYC Modulation around the CDK2/p27/SKP2 Axis |
| Q64990074 | MYC and RAS are unable to cooperate in overcoming cellular senescence and apoptosis in normal human fibroblasts. |
| Q33653686 | MYC and the control of DNA replication |
| Q37732974 | MYC in oncogenesis and as a target for cancer therapies |
| Q29619979 | MYC on the path to cancer |
| Q26783555 | MYC, Metabolism, and Cancer |
| Q60928825 | Mechanisms shaping the role of ERK1/2 in cellular senescence (Review) |
| Q38730348 | Melanocytic nevi and melanoma: unraveling a complex relationship |
| Q34997265 | Melanoma proliferation and chemoresistance controlled by the DEK oncogene |
| Q42038580 | Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response |
| Q42378381 | MiR-34a modulates ionizing radiation-induced senescence in lung cancer cells |
| Q59314000 | Mining Massive Amounts of Genomic Data: A Semiparametric Topic Modeling Approach |
| Q54702401 | Myc and a Cdk2 senescence switch. |
| Q37984547 | Narrowing the knowledge gaps for melanoma |
| Q35670683 | New Perspectives of "omics" Applications in Melanoma Research |
| Q39791081 | Noncatalytic function of ERK1/2 can promote Raf/MEK/ERK-mediated growth arrest signaling |
| Q35541658 | PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells |
| Q47927484 | Pathways from senescence to melanoma: focus on MITF sumoylation. |
| Q37777015 | Pathways of oncogene-induced senescence in human melanocytic cells |
| Q82417660 | Paying “Particle” Attention to Novel Melanoma Treatment Strategies |
| Q38674444 | Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines |
| Q33591386 | Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation |
| Q27438119 | Polycomb group protein Bmi1 is required for growth of RAF driven non-small-cell lung cancer |
| Q28583844 | Pseudo-DNA damage response in senescent cells |
| Q30657002 | RAB7 counteracts PI3K-driven macropinocytosis activated at early stages of melanoma development |
| Q28237793 | Raf kinases in cancer-roles and therapeutic opportunities |
| Q36926098 | Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes |
| Q37775417 | Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place? |
| Q39224402 | Ribonucleotide reductase and thymidylate synthase or exogenous deoxyribonucleosides reduce DNA damage and senescence caused by C-MYC depletion |
| Q89586306 | SENEBLOC, a long non-coding RNA suppresses senescence via p53-dependent and independent mechanisms |
| Q84759300 | SKI knockdown inhibits human melanoma tumor growth in vivo |
| Q92447468 | STAT3 Relays a Differential Response to Melanoma-Associated NRAS Mutations |
| Q35080064 | Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS) |
| Q27025648 | Small-molecule inhibitors of the Myc oncoprotein |
| Q39705986 | TCEAL7 inhibition of c-Myc activity in alternative lengthening of telomeres regulates hTERT expression |
| Q35008198 | TGF-beta signaling engages an ATM-CHK2-p53-independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells |
| Q37820202 | Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes |
| Q39671057 | Targeted nanoparticles deliver siRNA to melanoma |
| Q84966907 | Telomerase activity and telomerase reverse transcriptase expression induced by selenium in rat hepatocytes |
| Q42380380 | The Immortal Senescence |
| Q37728617 | The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy |
| Q41841005 | The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway |
| Q35212733 | The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site |
| Q33588743 | The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence |
| Q37239885 | The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects |
| Q34708265 | Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis |
| Q42617375 | Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs |
| Q39209913 | Vemurafenib induces senescence features in melanoma cells |
| Q40071869 | p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia |
| Q34186642 | p27Kip1 mediates addiction of ovarian cancer cells to MYCC (c-MYC) and their dependence on MYC paralogs |
| Q39810065 | p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. |
Search more.